Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease

This study has been completed.
Information provided by:
PRAECIS Pharmaceuticals Inc. Identifier:
First received: December 29, 2004
Last updated: September 18, 2006
Last verified: September 2006

This is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-moderate Alzheimer’s disease (AD). The primary objective of the study is to assess the safety of multiple IV injections of PPI-1019 in subjects with mild-moderate Alzheimer’s disease.

Condition Intervention Phase
Alzheimer's Disease
Drug: PPI-1019 (APAN)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease

Resource links provided by NLM:

Further study details as provided by PRAECIS Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Safety will be assessed through the occurrence of clinical adverse events and the occurrence of clinically significant changes from baseline.

Estimated Enrollment: 24
Study Start Date: December 2004
Estimated Study Completion Date: August 2005

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has the ability to understand the requirements of the study, provide written informed consent, and abide by the requirements of the study. In addition, a member of the subject’s family or a legally authorized representative must consent to the subject’s participation in the study.
  • Subject has a caregiver willing to assist the subject’s involvement in the study.
  • Subject is a male or female between the ages of 50 and 80 with a body mass index (BMI) below 31. Females must be post-menopausal at least 1 year or surgically sterilized.
  • Subject must have a cognitive deficit present for at least 1 year and meet DSM –IV criteria for Alzheimer’s disease and meet National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA) criteria for the presence of probable Alzheimer’s disease.
  • Subject’s severity of Alzheimer’s disease must be mild-moderate, documented with a Mini Mental State Exam (MMSE) score of 12-26.
  • Subject has a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within the prior 12 months which is compatible with a diagnosis of probable AD.
  • If a subject is being treated for Alzheimer’s disease, it must be with a single cholinesterase inhibitor (donepezil, rivastigmine, or galantamine), with or without memantine, and with a dose which has been stable for at least 3 months prior to dosing.
  • Subject performance status is ≤ 3 on items 1 through 5 and ≤ 2 on item 6 from the Degree of Disability Section of the “Rapid Disability Scale-2”
  • Subject agrees not to donate blood or blood products while participating in this study and for at least 60 days after discontinuing from the study.

Exclusion Criteria:

  • Subject has participated in a clinical trial of another investigational drug or device, or has taken any experimental drug within 30 days prior to admission to the Phase 1 unit. (Subjects previously enrolled in 1019-03-01 may be enrolled in 1019-04-01, only after a wash-out period of 45 days.)
  • Subject has a history compatible with vascular dementia as evidenced by a score of 5 or greater on the modified Hachinski Ischemia Scale.
  • Subject has evidence of clinically significant unstable cardiovascular, renal, hepatic, gastrointestinal, neurological, or metabolic disease within the past 6 months (as determined by medical history, ECG results, chest x-ray, or physical examination).
  • Subject performance status is > 3 on items 1 through 5 and > 2 on item 6 from the Degree of Disability Section of the “Rapid Disability Scale-2.”
  • Subject has diabetes that requires oral antidiabetic therapy or insulin.
  • Subject has a systolic blood pressure (sitting) of greater than 160 mmHg, a diastolic (sitting) greater than 95 mmHg, a decrease in systolic blood pressure of more than 30 mmHg upon standing for 2 minutes from a sitting or supine position, a pulse (sitting or supine) less than 50 or greater than 85.
  • Subject has any visual, hearing, or communication disabilities impairing his/her ability to participate in the study.
  • Subject is being treated with anticholinergics and/or clinically relevant cytochrome P450 3A4 inducers/inhibitors. The use of other concomitant medications for stable medical conditions is acceptable provided drug and dosage are stable for at least 4 weeks prior to dosing.
  • Subject is currently taking herbal supplements which interfere with drug metabolism, e.g. St. John’s wort, ginkgo biloba.
  • Subject has tested positive for drugs of abuse (amphetamines, barbiturates, cocaine, phencyclidine, or cannabinoids) on screening or Day -1
  • Subject has a current or past medical history of alcohol abuse.
  • Subject has any elevations (> 1.2 x ULN) on screening or Day -1 for ALT, AST, bilirubin, creatinine, blood urea nitrogen, or alkaline phosphatase.
  • Subject has any other screening or Day -1 laboratory values outside the normal ranges that are deemed clinically significant by the investigator.
  Contacts and Locations
Please refer to this study by its identifier: NCT00100334

United States, California
Silverado Senior Living
San Juan Capistrano, California, United States, 92675
Sponsors and Collaborators
PRAECIS Pharmaceuticals Inc.
  More Information

No publications provided Identifier: NCT00100334     History of Changes
Other Study ID Numbers: 1019-04-01
Study First Received: December 29, 2004
Last Updated: September 18, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by PRAECIS Pharmaceuticals Inc.:
Alzheimer's Disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders processed this record on April 17, 2014